{{Rsnum
|rsid=854555
|Gene=PON1
|Chromosome=7
|position=95301079
|Orientation=plus
|GMAF=0.4715
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=PON1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 11.5 | 51.3 | 37.2
| HCB | 30.1 | 51.5 | 18.4
| JPT | 40.2 | 50.0 | 9.8
| YRI | 54.8 | 43.2 | 2.1
| ASW | 49.1 | 36.8 | 14.0
| CHB | 30.1 | 51.5 | 18.4
| CHD | 38.0 | 48.1 | 13.9
| GIH | 14.9 | 43.6 | 41.6
| LWK | 66.1 | 25.7 | 8.3
| MEX | 26.3 | 47.4 | 26.3
| MKK | 38.6 | 47.7 | 13.7
| TSI | 9.8 | 39.2 | 51.0
| HapMapRevision=28
}}{{GWAS Summary
|SNP=rs854555
|PubMedID=18615156
|Condition=Treatment response to TNF antagonists
|Gene=PON1
|Risk Allele=A
|pValue=2.00E-006
|OR=NA
|95CI=
|OA=1
}}

{{PharmGKB
|RSID=rs854555
|Name_s=
|Gene_s=PON1
|Feature=Intron
|Evidence=PubMed ID:18615156
|Annotation=This variant is significantly associated with the efficacy of anti-TNF treatment in rheumatoid arthritis (Adjusted P-value: 0.000002; OR: 4.6 (1.8, 12.3)). The study is a genome-wide association study using the Illumina HapMap300 SNP chip on 89 RA patients prospectively followed after beginning of anti-TNF therapy.
|Drugs=adalimumab; etanercept; infliximab
|Drug Classes=
|Diseases=Arthritis, Rheumatoid
|Curation Level=Curated
|PharmGKB Accession ID=PA162928823
}}

{{PharmGKB
|RSID=rs854555
|Name_s=
|Gene_s=PON1
|Feature=Intron
|Evidence=PubMed ID:18615156; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS Results: Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in Rheumatoid Arthritis (Initial Sample Size: 89 cases; Replication Sample Size: NR; Risk Allele: rs854555-A). This variant is associated with Treatment response to TNF antagonists.
|Drugs=
|Drug Classes=
|Diseases=Arthritis, Rheumatoid
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356481
}}

{{PMID Auto
|PMID=20423481
|Title=Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study.
|OA=1
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs854555
|overall_frequency_n=54
|overall_frequency_d=124
|overall_frequency=0.435484
|n_genomes=38
|n_genomes_annotated=0
|n_haplomes=49
|n_articles=1
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}